Dr. Pazhaniyappan, BSMS
Published by Rathna Siddha Hospital & Herbal Research Centre, Chennai, Tamil Nadu, India
Abstract
Carcinoma breast and its associated oncological interventions frequently produce profound systemic disturbances extending beyond the primary malignant pathology. Chemotherapy and surgical management often induce severe physiological exhaustion, gastrointestinal dysfunction, inflammatory stress, respiratory compromise, disturbed sleep, anorexia, metabolic instability, and chronic pain, thereby significantly reducing quality of life and treatment tolerance. This clinical case study presents the longitudinal observation and Siddha supportive management of a 44-year-old female diagnosed with left-sided carcinoma breast in 2022, who underwent mastectomy in November 2025 followed by intensive chemotherapy in December 2025.
Immediately following chemotherapy, the patient developed critically reduced white blood cell counts associated with high fever, severe chest congestion, cough, respiratory distress, and generalized weakness requiring Intensive Care Unit stabilization. Following acute management, she was admitted to Rathna Siddha Hospital & Herbal Research Centre on December 31, 2025, for individualized Siddha supportive care aimed at restoring systemic adaptability and reducing post-chemotherapy toxic burden. Continuous monitoring was performed from January through April 2026 using daily symptom assessment, bowel and sleep analysis, respiratory observation, serial hematological investigations, liver function studies, inflammatory biomarkers, and tumor marker evaluation.
During the observational period, the patient demonstrated progressive symptomatic stabilization characterized by marked reduction in vomiting frequency, improved bowel regularity, relief from abdominal bloating, reduction in respiratory discomfort, improved sleep adaptability, and enhanced systemic tolerance. Although late biochemical investigations revealed progressive inflammatory tumor activity and hepatic stress, the patient achieved meaningful functional recovery and improved physiological stability by the time of discharge. This case illustrates the clinical relevance of prognosis-oriented Siddha supportive management in improving symptom adaptability, digestive regulation, inflammatory stabilization, and quality of life during advanced oncology care.
Introduction
Carcinoma breast remains one of the major causes of cancer-related morbidity among women worldwide. Despite considerable advances in surgery, chemotherapy, radiotherapy, and targeted oncology, many patients continue to experience severe systemic complications resulting from both malignant progression and aggressive therapeutic interventions. Persistent pain, digestive dysfunction, vomiting, disturbed sleep, inflammatory stress, cachexia, weakness, respiratory discomfort, and emotional exhaustion collectively diminish physiological resilience and compromise overall wellbeing.
Modern oncological treatment predominantly emphasizes tumor reduction and survival outcomes; however, long-term symptom burden frequently remains inadequately addressed. Chemotherapy-induced marrow suppression, gastrointestinal toxicity, hepatic overload, oxidative stress, and metabolic dysregulation generate a clinically unstable internal environment requiring continuous supportive care.
Within Siddha medicine, malignant disorders are interpreted as manifestations of deranged Vatham, Pitham, and Kabam associated with altered digestive metabolism, tissue depletion, toxic accumulation, and progressive weakening of physiological adaptability. Symptoms such as constipation, vomiting, migrating pain, inflammatory heat, abdominal bloating, anorexia, respiratory discomfort, and disturbed sleep indicate severe internal humoral disequilibrium.
At Rathna Siddha Hospital & Herbal Research Centre, a prognosis-oriented Siddha supportive model was adopted focusing on continuous observation of symptom fluctuations rather than isolated symptomatic suppression. Daily monitoring of bowel function, digestive tolerance, respiratory comfort, pain intensity, appetite variation, sleep rhythm, and systemic strength formed the basis for individualized therapeutic modification.
Patient Information and Clinical Presentation
The 44-year-old female from Tiruchirappalli, was diagnosed with carcinoma breast involving the left breast in 2022. She underwent left mastectomy in November 2025 followed by intensive chemotherapy on December 20, 2025. Within twenty-four hours of chemotherapy administration, she developed critically low white blood cell counts associated with high-grade fever, severe chest congestion, cough, respiratory distress, generalized weakness, and marked physical exhaustion requiring Intensive Care Unit stabilization.
Following ICU management, the patient continued to experience profound anorexia, vomiting tendency, epigastric burning sensation, abdominal bloating, constipation, disturbed sleep, respiratory discomfort, severe fatigue, and persistent rib and back pain. Clinical examination also revealed delayed healing changes around the postoperative left axillary region. The patient was admitted to Rathna Siddha Hospital & Herbal Research Centre on December 31, 2025, for prolonged Siddha supportive management intended to reduce post-chemotherapy systemic toxicity and restore physiological stability.
Siddha Clinical Interpretation and Therapeutic Strategy
From the Siddha perspective, the patient demonstrated advanced Vatha-Pitha derangement characterized by disturbed digestive fire, inflammatory toxic accumulation, altered metabolic transformation, weakened tissue nourishment, impaired bowel elimination, respiratory instability, and progressive depletion of systemic vitality. Persistent vomiting, severe constipation, migrating rib pain radiating toward the back, inflammatory gastric irritation, disturbed sleep, and fluctuating respiratory symptoms reflected severe internal humoral imbalance and reduced adaptive capacity.
The therapeutic strategy therefore emphasized digestive restoration, bowel normalization, inflammatory regulation, respiratory stabilization, pain moderation, enhancement of tissue adaptability, and preservation of systemic tolerance. Specialized Siddha formulations including Meme Homo Mithiyer tablets, Kodi Nelind preparations, Abroria Japan formulations, Grape Seed extracts, Cesalene Render syrup, Laadla drops, Vine Wormis, Farcomy tablets, and medicated ghee-based therapies were administered and dynamically modified according to daily physiological response patterns.
Longitudinal Prognostic Observation
The early phase during January 2026 demonstrated severe Vatha-Pitha aggravation associated with sharp floating pain involving the right rib region radiating toward the back, pricking sensation, epigastric burning, respiratory discomfort, gastric irritation, and fluctuating appetite. Although oxygen saturation gradually stabilized, profound weakness and digestive intolerance persisted.
During February 2026, the patient entered a fluctuating intermediate phase characterized by alternating periods of symptomatic relief and temporary aggravation. Improvement in pain intensity was occasionally accompanied by excessive drowsiness, poor appetite, generalized weakness, recurrent vomiting, severe gastric burning, and digestive instability. Nevertheless, gradual stabilization of respiratory tolerance and bowel rhythm became clinically evident over time.
The final observational phase began with readmission in April 2026. During the first week, persistent back pain, constipation, disturbed sleep, abdominal discomfort, and progressive drowsiness remained clinically significant. Subsequently, severe constipation associated with abdominal bloating precipitated recurrent vomiting episodes and marked sleep disturbance. Careful modification of Siddha supportive therapy resulted in progressive reduction of vomiting frequency, gradual improvement in abdominal discomfort, and improved bowel evacuation.
A major clinical turning point occurred between April 18 and April 19 when vomiting ceased completely and bowel movement normalized. Residual back pain persisted at a manageable intensity without major respiratory compromise. By April 20–22, the patient demonstrated meaningful functional recovery characterized by improved ambulation, restored respiratory comfort, normalized bowel function, improved sleep tolerance, reduced abdominal distress, and enhanced systemic adaptability. She was discharged in clinically stable condition on April 22, 2026.
Vital Signs Trend Monitoring
| Date | Clinical Phase | Blood Pressure (mmHg) | Pulse Rate (bpm) | SpO₂ (%) | Temperature | Clinical Interpretation |
| 31/12/2025 | Admission | 93/68 | 105 | 94 | Normal | Post-ICU systemic stress |
| 02/01/2026 | Early Phase | 110/90 | 109 | 95 | Normal | Active floating rib pain |
| 13/01/2026 | Early Phase | 89/60 | 90 | 99 | Normal | Improved oxygenation |
| 27/01/2026 | Readmission | 106/76 | 110 | 96 | Normal | Continued symptom monitoring |
| 15/02/2026 | Mid-Phase | 89/74 | 107 | 99 | Normal | Temporary hypotensive trend |
| 19/02/2026 | Mid-Phase | 115/85 | 114 | 99 | Normal | Hemodynamic recovery |
| 07/04/2026 | Late Phase | 118/94 | 112 | 99 | Normal | Persistent pain observation |
| 14/04/2026 | Late Phase | 138/97 | 112 | 99 | Normal | Mild systemic stress |
| 22/04/2026 | Discharge | 145/104 | 132 | 99 | Normal | Functional stabilization achieved |
Serial Hematological Assessment
| Parameter | 02/01/2026 | 13/01/2026 | 29/01/2026 | 18/04/2026 | Reference Range |
| RBC (10¹²/L) | 3.24 | 3.25 | 3.68 | 2.74 | 3.80–4.80 |
| Hemoglobin (g/dL) | 8.4 | 9.06 | 9.1 | 7.2 | 12.0–15.0 |
| WBC (/μL) | 12,950 | 4,930 | 4,660 | 6,190 | 4,000–10,000 |
| Neutrophils (%) | 80.1 | 81.3 | 86.3 | 74.7 | 40–70 |
| Platelets (10⁵/μL) | 1.45 | 5.29 | 2.94 | — | 1.50–4.10 |
The hematological profile demonstrated persistent moderate-to-severe anemia associated with chronic malignancy and post-chemotherapy marrow suppression. White blood cell fluctuations reflected the severity of post-chemotherapy immunological stress followed by gradual physiological stabilization during supportive care.
Tumor Marker and Biochemical Dynamics
| Investigation | Initial Observation | Lowest / Improvement Phase | Late Observation | Clinical Interpretation |
| CA-125 (U/mL) | 355.0 | 47.4 | 181.4 | Initial biochemical improvement followed by inflammatory flare |
| CA 15-3 (U/mL) | 687.0 | 43.6 | 916.0 | Progressive tumor-associated activity |
| Total Bilirubin (mg/dL) | 1.49 | — | 3.49 | Progressive hepatic stress |
| ALT (U/L) | 54.5 | — | 150.0 | Increasing hepatic inflammatory burden |
| Gamma-GT (U/L) | 172 | — | 303 | Progressive liver dysfunction |
| Serum Albumin (g/dL) | — | — | 2.5 | Cachectic metabolic depletion |
| CRP (mg/L) | Elevated | — | 83 | Persistent systemic inflammation |
| Ferritin (ng/mL) | 846 | — | 1,358 | Ongoing inflammatory activation |
| D-Dimer (ng/mL) | Elevated | — | 5,686 | Severe inflammatory and thrombotic stress |
Biochemical investigations demonstrated temporary tumor marker stabilization followed by progressive inflammatory and hepatic deterioration during the later phase of observation. Elevated inflammatory biomarkers reflected persistent systemic tumor-associated inflammatory activation.
Discussion
Advanced carcinoma patients frequently experience profound physiological exhaustion following chemotherapy and surgical intervention. Although modern oncology effectively targets malignant tissue, prolonged systemic symptom burden continues to significantly impair patient wellbeing and treatment tolerance. Gastrointestinal dysfunction, constipation, vomiting, inflammatory stress, marrow suppression, respiratory compromise, chronic pain, and metabolic instability collectively contribute toward reduced physiological adaptability and diminished quality of life.
This case demonstrates the potential supportive role of prognosis-oriented Siddha management in stabilizing fluctuating systemic symptoms during a vulnerable post-chemotherapy phase. Continuous monitoring of bowel rhythm, digestive tolerance, respiratory status, sleep quality, pain migration, appetite variation, and vomiting frequency allowed dynamic therapeutic modification according to changing physiological needs.
One of the most clinically significant observations was the progressive restoration of bowel regularity accompanied by complete cessation of vomiting during the late treatment phase. Improvement in gastrointestinal function appeared closely associated with enhanced sleep tolerance, reduced abdominal distress, improved respiratory comfort, and greater systemic stability. These observations support the Siddha principle that restoration of digestive equilibrium remains central to overall physiological recovery.
Although biochemical evidence later suggested progressive inflammatory tumor activity and hepatic burden, the patient nevertheless achieved meaningful functional stabilization and symptomatic improvement during the observation period. This distinction remains particularly important in advanced oncology supportive care where preservation of quality of life, reduction of suffering, and maintenance of physiological tolerance represent major therapeutic goals.
The Siddha supportive approach implemented at Rathna Siddha Hospital & Herbal Research Centre emphasized individualized adaptive care rather than isolated symptom suppression. Continuous prognosis-oriented observation, bowel-centered regulation, digestive restoration, inflammatory moderation, and systemic supportive therapy collectively contributed toward maintaining functional stability during a clinically complex oncological course.
Conclusion
This longitudinal clinical case study highlights the significance of individualized Siddha supportive management in patients experiencing severe systemic complications following aggressive oncological intervention for carcinoma breast. The patient presented with profound physiological compromise characterized by marrow suppression, respiratory distress, gastrointestinal dysfunction, inflammatory stress, chronic pain, disturbed sleep, hepatic burden, severe weakness, and reduced systemic adaptability after chemotherapy and mastectomy.
Through continuous prognosis-based Siddha supportive care, substantial symptomatic stabilization was achieved, particularly in the areas of vomiting control, bowel normalization, respiratory comfort, digestive regulation, pain moderation, and functional recovery. Despite progressive inflammatory and biochemical tumor activity during the late observation phase, the patient demonstrated improved daily physiological tolerance and meaningful enhancement in quality-of-life parameters.
This case supports the growing clinical relevance of integrative Siddha supportive care in advanced oncology management and underscores the need for further prospective research involving larger clinical cohorts, standardized Siddha therapeutic protocols, biomarker correlation, and long-term outcome analysis in integrative cancer care.
